Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC07-523LS + vorinostat
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
VRC07-523LS + vorinostat is a combination therapy investigated by the University of North Carolina at Chapel Hill as part of a "shock and kill" strategy for HIV-1 cure. The regimen consists of vorinostat (Zolinza), a small molecule histone deacetylase (HDAC) inhibitor, and VRC07-523LS, a potent broadly neutralizing monoclonal antibody (bNAb). Vorinostat acts as a latency-reversing agent (LRA) to induce the expression of latent HIV-1 proviruses from resting CD4+ T cells ("shock"). VRC07-523LS targets the CD4 binding site of the HIV-1 envelope glycoprotein gp120 and is intended to neutralize the reactivated virus and facilitate the clearance of infected cells through immune-mediated mechanisms ("kill"). Clinical studies have evaluated the safety and efficacy of this combination in HIV-positive individuals on suppressive antiretroviral therapy.
- Brand names
- Zolinza
- Other names
- suberoylanilide hydroxamic acid
02
Targets
HDAC6 (Histone deacetylase 6)FCGRT (Neonatal crystallizable fragment receptor)HDAC1 (Histone Deacetylase 1)gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on VRC07-523LS + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRC07-523LS + vorinostat.